These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 34238049

  • 1. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
    Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ.
    J Psychopharmacol; 2021 Aug; 35(8):890-900. PubMed ID: 34238049
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of treatments for bipolar depression.
    Vázquez GH, Holtzman JN, Tondo L, Baldessarini RJ.
    J Affect Disord; 2015 Sep 01; 183():258-62. PubMed ID: 26042634
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC.
    JAMA Psychiatry; 2018 Feb 01; 75(2):139-148. PubMed ID: 29282469
    [Abstract] [Full Text] [Related]

  • 4. Balancing benefits and harms of treatments for acute bipolar depression.
    Ketter TA, Miller S, Dell'Osso B, Calabrese JR, Frye MA, Citrome L.
    J Affect Disord; 2014 Dec 01; 169 Suppl 1():S24-33. PubMed ID: 25533911
    [Abstract] [Full Text] [Related]

  • 5. Treatment of bipolar depression: making sensible decisions.
    Citrome L.
    CNS Spectr; 2014 Dec 01; 19 Suppl 1():4-11; quiz 1-3, 12. PubMed ID: 25407667
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB.
    JAMA Psychiatry; 2019 Sep 01; 76(9):893-903. PubMed ID: 31166571
    [Abstract] [Full Text] [Related]

  • 7. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2011 Jan 19; (1):CD006626. PubMed ID: 21249678
    [Abstract] [Full Text] [Related]

  • 8. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M, Bartova L, Kasper S.
    Int J Neuropsychopharmacol; 2020 Jul 29; 23(7):440-445. PubMed ID: 32570275
    [Abstract] [Full Text] [Related]

  • 9. Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?
    Thase ME.
    Psychiatr Clin North Am; 2016 Sep 29; 39(3):477-86. PubMed ID: 27514300
    [Abstract] [Full Text] [Related]

  • 10. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2010 Mar 17; (3):CD006654. PubMed ID: 20238348
    [Abstract] [Full Text] [Related]

  • 11. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008121. PubMed ID: 21154393
    [Abstract] [Full Text] [Related]

  • 12. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L, Ketter TA, Cucchiaro J, Loebel A.
    J Affect Disord; 2014 Feb 08; 155():20-7. PubMed ID: 24246116
    [Abstract] [Full Text] [Related]

  • 13. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
    Jha MK, Mathew SJ.
    Am J Psychiatry; 2023 Mar 01; 180(3):190-199. PubMed ID: 36855876
    [Abstract] [Full Text] [Related]

  • 14. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M, Krupka-Matuszczyk I.
    Hum Psychopharmacol; 2011 Jan 01; 26(1):81-5. PubMed ID: 23055416
    [Abstract] [Full Text] [Related]

  • 15. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.
    Kato M, Chang CM.
    CNS Drugs; 2013 May 01; 27 Suppl 1():S11-9. PubMed ID: 23709358
    [Abstract] [Full Text] [Related]

  • 16. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2015 Sep 01; 69(9):978-97. PubMed ID: 26250067
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.
    Am J Psychiatry; 2019 Jun 01; 176(6):428-438. PubMed ID: 31109201
    [Abstract] [Full Text] [Related]

  • 18. A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (Journal of Psychopharmacology, 2021, Vol. 35(8) 890-900).
    Terao I, Honyashiki M, Inoue T.
    J Psychopharmacol; 2022 May 01; 36(5):653-654. PubMed ID: 35475361
    [No Abstract] [Full Text] [Related]

  • 19. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.
    Encephale; 2004 May 01; 30(5):417-24. PubMed ID: 15627046
    [Abstract] [Full Text] [Related]

  • 20. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M, Dell'osso L, Kasper S, Pitchot W, Dencker Vansvik E, Köhler J, Jørgensen L, Montgomery SA.
    J Affect Disord; 2013 Oct 01; 151(1):209-19. PubMed ID: 23810357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.